B-cell receptor recognizing Herpes Simplex Virus type 2 glycoprotein antigens (BCR)

B-cell receptors (BCRs) recognizing HSV-2 glycoprotein antigens are specialized transmembrane proteins on B lymphocytes that play a pivotal role in the adaptive immune defense against Herpes Simplex Virus type 2 [UniProt: P11912]. These receptors are designed to specifically identify and bind to viral surface glycoproteins, such as gD, gB, and the gH/gL complex, which are critical for the virus's ability to infect host cells [PubMed: 25231300]. Binding of these viral antigens to the BCR initiates a complex signaling cascade that drives B-cell activation, leading to the production of high-affinity neutralizing antibodies and the establishment of long-term immunological memory [PubMed: 31434734]. In the field of drug development, these receptors are the primary focus of vaccine strategies, such as mRNA-1608 and BNT163, where synthetic or recombinant antigens are used to stimulate a protective immune response [ClinicalTrials.gov: NCT05213312, NCT05432583]. Additionally, the study of these BCRs allows researchers to isolate and develop monoclonal antibodies that can be used as passive immunotherapy to prevent or treat HSV-2 infections, particularly in vulnerable populations. Understanding the interaction between the BCR and HSV-2 antigens is essential for overcoming the challenges of viral latency and recurrent outbreaks.

Other names

HSV-2-specific B-cell receptorAnti-HSV-2 BCRGlycoprotein-specific B-cell receptorSurface immunoglobulin recognizing HSV-2

Antigen-mediated cross-linking of B-cell receptors triggers intracellular signaling via the Ig-alpha/Ig-beta complex, leading to B-cell proliferation, affinity maturation, and differentiation into antibody-secreting plasma cells [UniProt: P11912, PubMed: 31434734].